A

ADARx Pharmaceuticals, Inc.

ADRXPriced

ADARx Pharmaceuticals, Inc. · Nasdaq Global Market · latest filing 2026-09-28

Report source
One-minute decisionBASIC RESEARCHSource completeness · 86%

ADARx priced its IPO at $17, with AbbVie participation and substantial clinical-stage funding needs.

As of the September 28, 2026 Form 424B4, ADARx proposed 26.25 million primary shares at $17.00 and a concurrent AbbVie private placement.

Where does the money go?Awaiting verification424B4 · 2026-09-28
Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointThe filing states expected delivery on or about September 28, 2026; completion and confirmed trading require subsequent verification.424B4 · 2026-09-28

Capital destination

Awaiting verification

424B4 · 2026-09-28

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗
Next checkThe filing states expected delivery on or about September 28, 2026; completion and confirmed trading require subsequent verification.
Latest filing2026-09-28

Capital destination

Awaiting verification

424B4 · 2026-09-28

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · 424B4 ↗
BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSED

Names not yet published

Dilution and valuation

IPO priceAwaiting verification
Basic post-offer106,801,325
Fully diluted sharesAwaiting verification
Value—
Dilution and valuation
CalculationSharesValueReference
Post-offer shares106,801,325—Immediately after offering and concurrent private placement; no overallotment · The offering

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · 424B4 ↗

Holder data awaits verification

Post-offer shares are based on 75,318,061 shares after preferred conversion, plus the IPO and AbbVie placement. Existing officers, directors and >5% holders are described as holding approximately 54% in aggregate; the supplied evidence does not provide full holder-by-holder voting totals. · 2026-09-28

Post-offer shares are based on 75,318,061 shares after preferred conversion, plus the IPO and AbbVie placement. Existing officers, directors and >5% holders are described as holding approximately 54% in aggregate; the supplied evidence does not provide full holder-by-holder voting totals.

One disclosed holder; not a complete ownership distribution.Check the source · 424B4 ↗

Conditional lock-up timeline

StatusReference
Awaiting verificationSource ↗

Financial quality and runway

StatusReference
Awaiting verificationSource ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

The company has not completed any clinical programs and has no products approved for commercial sale.

Potential impact
Awaiting verification
Monitor
The filing states expected delivery on or about September 28, 2026; completion and confirmed trading require subsequent verification.
SEC EDGAR

424B4

2026-09-28

Open SEC filing ↗